Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16133338 | 0.87 | ALDH1A1 (0.30) | — | |
| Hydrochloric Acid SCHEMBL10805157 | 0.85 | LMNA (0.35) | — | |
| SCHEMBL4529746 | 0.82 | MAOA (0.44) | MAOAMAOB | |
| SCHEMBL3352929 | 0.78 | ALDH1A1 (0.48) | — | |
| SCHEMBL12081765 | 0.78 | PAOX (0.34) | — | |
| SCHEMBL16133337 | 0.76 | ALDH1A1 (0.47) | — | |
| SCHEMBL8928213 | 0.76 | LMNA (0.39) | — | |
| SCHEMBL8928215 | 0.75 | LMNA (0.38) | — | |
| SCHEMBL1203464 | 0.74 | KDM4E (0.32) | — | |
| SCHEMBL28676072 | 0.73 | KDM4A (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117800868-A | Low-viscosity self-thixotropic polyaspartic acid ester and preparation method and application thereof | 深圳飞扬骏研新材料股份有限公司 | 2024-04-02 | — | — | CN | claimed |
| CN-117800868-B | Low-viscosity self-thixotropic polyaspartic acid ester and preparation method and application thereof | 深圳飞扬骏研新材料股份有限公司 | 2026-02-13 | — | — | CN | disclosed |
| CN-117800868-A | Low-viscosity self-thixotropic polyaspartic acid ester and preparation method and application thereof | 深圳飞扬骏研新材料股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117800868-A | Low-viscosity self-thixotropic polyaspartic acid ester and preparation method and application thereof | 深圳飞扬骏研新材料股份有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-7947839-B2 | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use | GENENTECH, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| EP-1817059-A2 | CONJUGATES OF 1,8-BIS-NAPHTHALIMIDES WITH AN ANTIBODY | Genentech, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2007064345-A9 | HETEROCYCLIC-SUBSTITUTED BIS-1,8 NAPHTHALIMIDE COMPOUNDS, ANTIBODY DRUG CONJUGATES, AND METHODS OF USE | GENENTECH INC (US) | 2007-07-12 | — | — | WO | disclosed |
| US-20070134243-A1 | Antibody drug conjugates and methods | GENENTECH, INC. | 2007-06-14 | — | — | US | disclosed |
| US-20060182751-A1 | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use | GENENTECH, INC. (US) | 2006-08-17 | — | — | US | disclosed |
| WO-2006060533-A2 | CONJUGATES OF 1, 8-BIS-NAPHTHALIMIDES WITH AN ANTIBODY | GENENTECH, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060182751-A1 | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use | CCNY, CCNI, MKI67 | MAOA 1289/4885MAOB 1266/4885 |
| US-20070134243-A1 | Antibody drug conjugates and methods | BOD1L1, MKI67, CCNI | MAOA 1453/4885MAOB 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.